Navigation Links
A protein called cFLIP makes tumor cells in breast cancer resistant to treatments
Date:12/14/2010

This release is available in Spanish.

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine (CABIMER) and the University of Granada found that cFLIP an inhibitor of death ligand-induced apoptosis is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells.

Researchers proved that a variation in the expression of this protein may lead to the normal development of breast epithelium. This is an important finding to be considered in the design of cFLIP-targeted therapies against cancer.

The research conducted by Rosario Yerbes Cadenas, PhD candidate at the University of Granada, was led by professor Abelardo Lpez Rivas, of CABIMER, and was aimed at analysing the potential of cFLIP inhibitors in cancer therapies.

At present, TRAIL is a death-ligand of the TNF family, with significant therapeutic potential against cancer, basically due to its ability to induce apoptosis in cancer cells without displaying significant toxicity toward normal cells. However, there are tumor cells that are resistant to TRAIL-induced apoptosis for unknown causes.

A Key Component

This study analysed the role of cFLIP in breast cancer cells' resistance to TRAIL-induced apoptosis. Thus, researchers concluded that cFLIP is key in these cells' resistance to TRAIL. Such conclusion was drawn from the evidence that the inhibition of their expression through treatments with Doxorubicin (anthracycline, widely used in chemotherapy) or with SAHA (Histone deacetylases inhibitor), as well as the silencing of its expression through cFLIP siRNA oligos (small interfering RNA), resulted in the sensitisation of breast cancer cells to TRAIL-induced apoptosis.

The authors of this research proved that cFLIP plays a survival role in tumorous and non-tumorous breast epithelial cells, since the inhibition of its expression induces apoptosis. This type of apoptosis requires the formation of the death-inducing signalling complex, which includes TRAIL-R2 receptor, adapter molecule FADD and procaspase-8- but is TRAIL-independent itself.

Conversely, in the light of the cFLIP relevance in controlling apoptosis, researchers studied the role of cFLIP in breast epithelial cells MCF-10A morphogenesis -a process where apoptosis plays an essential role. Thus, cFLIPL/cFLIPS overexpression inhibits lumen formation in acini from breast epithelial cells when they are cultured in a 3D extracellular matrix (3D cultures). Additionally, inhibition of cFLIP expression prevents the development of acini, since cells with low expression of cFLIP are unfeasible.

For this reason, regulation of cFLIP expression was very relevant to this research. Scientists determined that the PI3K/AKT signalling pathway is not the main responsible for cFLIP synthesis in breast cancer cell, but may be it is NF-kB pathway.

Additionally, this study revealed that the ubiquitin-proteasome system plays a key role in cFLIP cell degradation. At present, researchers are trying to identify E3-ubiquitin ligase protein, responsible for cFLIP degradation by such system.


'/>"/>

Contact: Rosario Yerbes Cadenas
Rosario.yerbes@cabimer.es
34-954-467-934
University of Granada
Source:Eurekalert

Related biology news :

1. Firefly protein lights pathway to improved detection of blood clots
2. Dynamics of chaperone protein critical in rescuing brains of Alzheimers mice from neuron damage
3. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
4. Proteins, like people, act differently when crowded together
5. MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors
6. Uptake protein acts as zincs doorway to the cell
7. Modulating a protein in the brain could help control Alzheimers disease
8. Process leading to protein diversity in cells important for proper neuron firing
9. A stem cell secreted protein can be given to improve heart function after experimental heart attack
10. Structure of a protein related to heart and nervous system health revealed
11. Synapses recycle proteins for the release of neurotransmitters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: